Digital Therapeutics Sarcopenia Market Report 2026

The digital therapeutics sarcopenia market size has grown rapidly in recent years. It will grow from $1.54 billion in 2025 to $1.78 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to rising aging population prevalence, increased awareness of sarcopenia-related health risks, expansion of telehealth adoption, growing acceptance of software-based medical therapies, early clinical validation of digital interventions.

The digital therapeutics sarcopenia market size is expected to see rapid growth in the next few years. It will grow to $3.21 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to increasing demand for home-based chronic condition management, rising integration of ai-driven therapeutic personalization, expansion of reimbursement support for digital therapeutics, growing adoption of remote patient monitoring, increasing focus on preventive muscle health solutions. Major trends in the forecast period include increasing adoption of personalized digital therapy programs, rising use of wearable-integrated muscle monitoring, growing deployment of remote physiotherapy platforms, expansion of data-driven sarcopenia management solutions, enhanced focus on patient engagement and adherence.

The rising prevalence of comorbidities is expected to drive the growth of the digital therapeutics sarcopenia market in the coming years. Comorbidities refer to the presence of two or more health conditions in a single individual. The increase in comorbidities is largely due to an aging population, as advancing age heightens the risk of multiple chronic conditions because of declining physiological functions and prolonged exposure to health risks. Digital therapeutics for sarcopenia help prevent comorbidities, particularly obesity, by encouraging regular physical activity and muscle strengthening, which improve metabolism and reduce fat accumulation. For example, in March 2024, the World Obesity Federation, a UK-based membership organization, reported that nearly 79% of adults affected by overweight and obesity are projected to live in low- and middle-income countries by 2035, with the total number of adults with obesity expected to reach 1.53 billion. Consequently, the growing prevalence of comorbidities is fueling the expansion of the digital therapeutics sarcopenia market.

Major companies in the digital therapeutics sarcopenia market are focusing on developing advanced solutions, such as drug discovery platforms, to create more targeted therapies, improve treatment outcomes, and accelerate personalized care for age-related muscle loss. A drug discovery platform enables faster and more effective development of new drugs using advanced tools and methods. For instance, in April 2025, ProFuse Technology, an Israel-based biotechnology company, launched a drug discovery platform aimed at preventing muscle loss caused by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By using lab-grown, highly mature muscle tissues that replicate natural muscle, the company can test and screen drug candidates more accurately and efficiently. This platform also reduces reliance on animal testing and lowers research costs. As demand for muscle-preserving therapies grows, ProFuse is expanding from cultivated meat into biopharma, offering an innovative solution to address increasing muscle health challenges.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Versanis Bio for $1.9 billion. This acquisition expands Lilly's portfolio to include Versanis' key asset, bimagrumab, which is currently being tested in a Phase 2b trial both alone and in combination with semaglutide in individuals with overweight or obesity. Versanis Bio, based in the US, specializes in developing treatments for sarcopenia.

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital therapeutics sarcopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the digital therapeutics sarcopenia market by increasing costs of imported wearable devices, sensors, monitoring hardware, and supporting electronic components required for integrated therapy platforms. Healthcare providers and digital health companies in North America and Europe are most affected due to dependence on imported hardware, while Asia-Pacific faces cost pressures in device manufacturing and software-hardware integration. These tariffs are raising deployment costs and slowing large-scale rollout in clinical and homecare settings. However, they are also encouraging domestic device production, regional technology partnerships, and localized development of software-centric therapeutic ecosystems that reduce long-term hardware dependence.

The digital therapeutics sarcopenia market research report is one of a series of new reports that provides digital therapeutics sarcopenia market statistics, including digital therapeutics sarcopenia industry global market size, regional shares, competitors with a digital therapeutics sarcopenia market share, detailed digital therapeutics sarcopenia market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics sarcopenia industry. This digital therapeutics sarcopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digital therapeutics for sarcopenia are evidence-based, software-driven interventions designed to prevent, manage, or treat sarcopenia, a condition marked by the progressive loss of muscle mass, strength, and function. These interventions use digital platforms to deliver personalized therapeutic strategies grounded in clinical evidence and behavioral science.

The primary offerings in digital therapeutics for sarcopenia include software, devices, and services. The software component delivers personalized interventions, such as exercise programs and dietary plans, through digital devices to help users manage muscle loss and support recovery. These solutions are distributed via various channels, including online platforms, pharmacies, and others, and their applications cover areas such as muscle strengthening, physical activity tracking, and nutrition management. They are utilized by a range of end users, including hospitals and clinics, homecare settings, rehabilitation centers, and others.

The digital therapeutics sarcopenia market consists of revenues earned by entities by providing services such as software-driven therapeutic interventions, integration of predictive analytics, and delivery of rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics sarcopenia market also includes sales of wearable devices, biosensors, and virtual and augmented reality tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.